Skip to main content
SpringerLink
Log in

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90.

    Article  CAS  PubMed  Google Scholar 

  2. Hofman MS, Sandhu S, Eu P, Price J, Akhrust T, Iravani A, et al. Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA. Ann Oncol. 2017;28(Suppl 5).

  3. Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schafers M, Essler M, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2017.

  4. Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, et al. Phase III study of Cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34(25):3005–13.

    Article  CAS  PubMed  Google Scholar 

  5. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402–18.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital Muenster, 48149, Münster, Germany

    Kambiz Rahbar

  2. Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

    Hojjat Ahmadzadehfar

  3. Department of Urology, University Hospital Muenster, Münster, Germany

    Martin Boegemann

Authors
  1. Kambiz Rahbar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hojjat Ahmadzadehfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Boegemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kambiz Rahbar.

Ethics declarations

Disclosure

The University of Münster received consulting fees from ABX Advanced Biochemical Compounds, Radeberg, Germany, for KR and MB. The authors declare they have no conflicts of interest according to the subject and matter of the presented article.

Conflict of interest

The authors declare that they have no financial or non-financial competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rahbar, K., Ahmadzadehfar, H. & Boegemann, M. 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?. Eur J Nucl Med Mol Imaging 45, 513–514 (2018). https://doi.org/10.1007/s00259-017-3892-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3892-0

Search

Navigation